Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Described herein are compositions comprising a nitric oxide releasing material comprising a (i) a polysiloxane network and (ii) a plurality of nitric oxide-donating moieties covalently bonded to the polysiloxane network; and (b) a silicone oil. Also described herein are articles composed of the compositions described herein and methods for using the same. The compositions described herein provide highly sustained, long-term nitric oxide release that have numerous biological activities such as, for example, preventing localized platelet activation, fibrinogen adhesion, and biofilm formation for a prolonged period of time.

A nitric oxide administration device 1 includes a first flow path 101 including a first intake port 101a and an oxygen supply port 101b, an oxygen generation unit 100 which is arranged in the first flow path 101 and which generates concentrated oxygen from air introduced via the first intake port 101a, the generated concentrated oxygen being supplied via the oxygen supply port 101b, a second flow path 201 which is branched from the first flow path 101 and which includes an NO supply port 201b, and an NO generation unit 200 which is arranged in the second flow path 201 and which generates NO from gas distributed from the first flow path 101, the generated NO being supplied via the NO supply port 201b.

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO.sub.2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO.sub.2-to-NO reactor cartridge and/or a breakthrough of NO.sub.2, and providing an indication of the remaining useful life and/or breakthrough.

A nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid N.sub.2O.sub.4, activate upon operator demand, convert N.sub.2O.sub.4 to NO.sub.2 via a heating element(s) controlled by a console to deliver NO.sub.2 at a controlled flow rate, direct concentrated NO.sub.2 to a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.

A nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid N.sub.2O.sub.4, activate upon operator demand, convert N.sub.2O.sub.4 to NO.sub.2 via a heating element(s) controlled by a console to deliver NO.sub.2 at a controlled flow rate, direct concentrated NO.sub.2 to a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NO.sub.2 to NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO.sub.2-to-NO reactor cartridge and/or a breakthrough of NO.sub.2, and providing an indication of the remaining useful life and/or breakthrough.

The present disclosure is drawn to methods and compositions for treating infections and minimizing transmissibility. The method can comprise treating a subject for infection with Severe Acute Respiratory Syndrome Coronavirus (SARSr-CoV) comprising administering a therapeutically effective amount of a nitric oxide releasing solution (NORS) to the subject. The NORS can be administered as a spray having an average droplet volume which contains treatment within the upper respiratory tract. The method of minimizing subject-to-subject transmissibility for a pathogen can comprise administering a therapeutically effective amount of a nitric oxide releasing solution (NORS) to the subject. NORS can include at least one nitric oxide releasing compound and acidifying agent, which can release a therapeutically effective amount of spray having an average droplet volume which contains treatment within the upper respiratory tract.

A moisture or hydrating liquid activatable solid formulation for nitric oxide (NO) generation includes a nitrite source; a copper (I) or copper (II) catalyst; an NO generation accelerant; and a solid pH buffer. The nitrite source is to generate NO when exposed to an effective amount of moisture or a hydrating liquid. The pH buffer is present in an amount sufficient to render a pH of the moisture or hydrating liquid activatable solid formulation from greater than 4 to about 9.0.

A moisture or hydrating liquid activatable solid formulation for nitric oxide (NO) generation includes a nitrite source; a copper (I) or copper (II) catalyst; an NO generation accelerant; and a solid pH buffer. The nitrite source is to generate NO when exposed to an effective amount of moisture or a hydrating liquid. The pH buffer is present in an amount sufficient to render a pH of the moisture or hydrating liquid activatable solid formulation from greater than 4 to about 9.0.